Nutex Health has undergone a dramatic transformation, with gross margins expanding from 15.1% in 2024Q1 to 67.0% in 2026Q2 and operating margins reaching 57.8%, while the balance sheet has deleveraged from a D/E of 3.40 to 0.51. The company generated $106.0M i...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $9.38+89.5% vs $4.95 | $211M-2.0% vs $215M |
Q2 2026 Apr 30, 2026 | $6.52+63.4% vs $3.99 | $216M-5.0% vs $228M |
Q2 2026 Mar 5, 2026 | $1.61-71.0% vs $5.56 | $152M-41.4% vs $259M |
Q4 2025 Nov 19, 2025 | $7.76+328.7% vs $1.81 | $268M+25.3% vs $214M |
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX) today announced that it has received approval to dual-list its common stock on Nasdaq Texas.
Nutex Health Inc. (NASDAQ: NUTX - Get Free Report) Director Scott Saunders sold 203 shares of the business's stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $214.25, for a total transaction of $43,492.75. Following the transaction, the director owned 400 shares in the company, valued at approximately
EDRY, VNCE, NUTX, TXO and KB show strong recent price momentum despite a volatile September, backed by improving earnings expectations.
Nutex Health Inc. (NASDAQ: NUTX - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the
Benchmark NUTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nutex Health, Inc. (NUTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $212.31 | $1.46B | 20.26 | 82.36% | 8.09% | 22.64% | 5.18% | |
| $111.70 | $2.08B | 21.44 | 23.21% | 7.13% | 9.57% | — | |
| $23.68 | $442.91M | 9.59 | 2.63% | 14% | 18.37% | — | |
| $175.07 | $10.6B | 7.58 | 9.71% | 8.42% | 20.37% | — | |
| $253.97 | $21.88B | 16.40 | 3.12% | 10.27% | 25.45% | — | |
| $2.75 | $387.77M | 0.73 | -1.18% | -1.34% | — | — |
Nutex Health, Inc. (NUTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nutex Health, Inc. (NUTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 21, 2026·SEC
Apr 30, 2026·SEC
Get notified when NUTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nutex Health, Inc. (NUTX) stock FAQ — growth, dividends, profitability & financials explained
Nutex Health, Inc. (NUTX) reported $846.7M in revenue for fiscal year 2025. This represents a 66763% increase from $1.3M in 2010.
Nutex Health, Inc. (NUTX) grew revenue by 82.4% over the past year. This is strong growth.
Yes, Nutex Health, Inc. (NUTX) is profitable, generating $179.9M in net income for fiscal year 2025 (8.1% net margin).
Yes, Nutex Health, Inc. (NUTX) pays a dividend with a yield of 5.18%. This makes it attractive for income-focused investors.
Nutex Health, Inc. (NUTX) has a return on equity (ROE) of 22.6%. This is excellent, indicating efficient use of shareholder capital.
Nutex Health, Inc. (NUTX) generated $348.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
